Company Overview

GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and services to global preclinical R&D communities. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.

GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing and mouse phenotyping, CRISPR/Cas9 gene-editing, cryopreservation, rapid expansion, and customized breeding. The company has developed one of the world's largest collections of mouse models to enable scientific innovation and accelerate drug development.

Learn about our parent company here.

Genetically Engineered Mouse Models Driving Innovation

Our History

2017

GemPharmatech Co. Ltd. Founded

Parent company GemPharmatech Co. Ltd. established with headquarters in Nanjing, China.

2018

Knockout All Project (KOAP) Initiated

Knockout All Project (KOAP) initiated to establish a comprehensive library of knockout (KO) and conditional knockout (cKO) mice for all protein coding genes in the mouse genome.

2019

Humanized Model Development

Developed humanized animal models and opened a branch in Changzhou to expand production capacity.

2020

GemPharmatech US Launched

Obtained germ-free animal production license, expanded production base by opening facilities in Chengdu and Guangzhou, and launched GemPharmatech LLC to serve the North American and European markets.

2021

17,000+ Genetically Engineered Mouse Models

Library reached 17,000+ genetically engineered mouse models (GEMMs), expanded productdion capacity by opening facilities in Beijing, China.

Leadership Team

Mark W. Moore, PhD

Chief Executive Officer

Mark is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, he was a co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company, and later served as the Executive Director of the International Mouse Phenotyping Consortium (IMPC). He received his Ph.D. in Biology from Brandeis University studying antibody gene recombination using transgenic mice.

Zhiying Li, PhD

Director, Life Science and Technology

Zhiying is a trained neuroscientist with a doctoral degree from Harvard University. She conducted her postdoctoral research at Rockefeller University. Prior to joining GemPharmatech, she worked at Taconic Biosciences, providing scientific support to both commercial products and scientific services. She is a firm believer in ethical use of research animals and their invaluable contribution to biomedical research for the benefit of human health.

Brook White

Senior Director, Sales and Marketing

Brook has held senior marketing executive positions in a number of life sciences companies and has over 20 years of experience in the industry. Her prior experience includes working with companies in clinical trial technology, the clinical CRO space, and CDMO space.  She is responsible for leading GemPharmatech’s marketing and sales operations in the US.

Jeremy Steuhl

Director, Information Technology

Jeremy is a veteran of the US Navy, where he began his career as an Intelligence Analyst and developed his enthusiasm for Information Technology.  Prior to joining GemPharmatech, Jeremy was the head of global business applications at Taconic Biosciences, where he was responsible for leading international teams in the implementation and support of life science solutions.

Santi Suryani Chen, PhD

Associate Director, Immunology and Oncology

Santi is a research scientist and business development professional with over 10 years of experience in autoimmune disease, immunology, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia, focusing on pediatric leukemia and therapies. Her projects include testing agents' efficacy and mechanisms such as navitoclax, venetoclax, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards.